Toronto, Ontario--(July 8, 2021) - Datametrex AI Limited (the "Company" or "Datametrex") (TSXV: DM) (FSE: D4G) (OTCQB: DTMXF) is pleased to announce that the Company conducted approximately 62,000 COVID-19 tests for the Film and Production industry in Toronto, Vancouver, and Montreal, and sold over 50,000 1 Copy PCR test kits during the second quarter.
"The company is pleased with the testing and sales volume in the COVID-19 business. With the new highly contagious Delta variant spreading around the world, management feels that continued testing will be essential for the immediate future as part of the answer to keep people secure and healthy," said Marshall Gunter, Chief Executive Officer of the Company.
The Company continues to have success with the 1copy™ COVID-19 qPCR Multi Kit, ("1drop"). The manufacturer, 1drop Inc., has confirmed that the 1drop can identify the new variants of the coronavirus that causes COVID-19, now circulating worldwide which is vital to stemming the many variants including the Delta variant that are spreading locally in Canada.
Datametrex AI Limited is a technology-focused with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex's mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, Company provides progressive solutions to support the supply chain.
For additional information on Datametrex and other corporate information, please visit the Company's website at www.datametrex.com.
For further information, please contact:
Marshall Gunter - CEO Phone: (514) 295-2300 Email: firstname.lastname@example.org
Neither the TSX Venture Exchange nor it's Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
All statements included in this press release that address activities, events, or developments that the Company expects, believes, or anticipates will or may occur in the future are forward-looking statements. These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections, and other forward-looking statements will prove inaccurate, certain of which are beyond the Company's control. Readers should not place undue reliance on forward-looking statements. Except as required by law, the Company does not undertake to revise or update these forward-looking statements after the date hereof or revise them to reflect the occurrence of future unanticipated events.